Patented Medicine Prices Review Board will hear allegations of breach of reporting requirements for leukemia drug

The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Baxalta Corporation failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations.

About Canada News Centre - National News